FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright

Altimmune, Inc. (NASDAQ:ALT) – Research analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Altimmune in a report released on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($1.28) per share for the year, down from their previous estimate of ($1.25). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Altimmune’s Q1 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at ($1.45) EPS and FY2028 earnings at ($0.15) EPS.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million during the quarter. During the same quarter in the previous year, the business posted ($0.39) EPS.

ALT has been the subject of a number of other reports. B. Riley reaffirmed a “buy” rating and set a $20.00 price objective on shares of Altimmune in a research report on Monday, August 12th. UBS Group assumed coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Finally, Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Altimmune Trading Up 4.5 %

Shares of NASDAQ ALT opened at $7.47 on Monday. Altimmune has a 12 month low of $2.41 and a 12 month high of $14.84. The stock has a 50 day moving average of $7.05 and a 200-day moving average of $6.91. The company has a market capitalization of $531.27 million, a P/E ratio of -4.82 and a beta of 0.09.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Swiss National Bank bought a new position in shares of Altimmune in the 1st quarter valued at $1,079,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Altimmune during the first quarter worth $271,000. Sei Investments Co. bought a new position in Altimmune during the 1st quarter worth $479,000. SG Americas Securities LLC lifted its holdings in Altimmune by 542.8% during the 2nd quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after buying an additional 214,968 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after buying an additional 335,444 shares during the period. 78.05% of the stock is owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.